NCT03033836View on ClinicalTrials.gov

Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

June 28, 2019

Study Completion Date

June 28, 2019

Conditions
HIV Infections
Interventions
DRUG

ARV treatment

Dolutegravir 50 mg QD plus co-formulated emtricitabine 200 mg/tenofovir 300 mg QD.

Trial Locations (1)

C1202ABB

Fundacion Huesped, Ciudad de Buenos Aires

Sponsors

Collaborators (1)

ViiV Healthcare
All Listed Sponsors
collaborator

ViiV Healthcare

INDUSTRY

lead

Fundación Huésped

OTHER